|Day Low/High||6.49 / 6.90|
|52 Wk Low/High||2.60 / 12.42|
Premarket futures are still pointing to a higher opening as we get the January U.S. jobs report. It's going to be interesting to see how the market reacts to the numbers. At this point, I don't know what would be better for stocks. A strong report w...
A so-called "pyramid strategy" can help you enter the depressed sector.
If there were a Super Bowl for stocks, these companies could win.
The market is off to a tepid start after rallying for three straight days -- certainly understandable, and some profit taking should be expected as we trade up near the highs of the relatively narrow trading range that has existed throughout most of...
This small-cap biotech firm could be in the early stages of a big move.
The market opened on a very strong note and Biogen Idec is up big after announcing study of its experimental drug for Alzheimer's disease had exceeded expectations. The whole biotech sector is having another strong day after yesterday's huge outper...
This vaccine maker is now closer to several important milestones.
But looks like the second-worst weekly loss of the year. The market continues to post losses across the board, but is off the lows of the day. Looks like equities are heading to their second-worst weekly loss of the year. The 10 year Treasuries loo...
Though broad futures have improved somewhat. Market futures are still pointing to a down open, but they have improved somewhat since my first Diary post this morning. Meantime, oil just can't get any love. The International Energy Agency (IEA) has c...
The market seems to be severely discounting DynaVax's chances of approval for its hep-B treatment.
Senior columnist Adam Feuerstein says Dynavax Technologies is the next big thing to watch in biotech.